The stakes are high on both sides: for patients who depend on these treatments, and for providers who face potential enforcement risk if they continue prescribing compounds that ultimately are not approved for the 503A Bulks List
BPC-157 and TB-500 (thymosin -4) are research compounds with no approved human or veterinary drug product
Daily Protocol: 1-2 mg subcutaneous injection, administered at the same time each day Alternative Protocol: 2 mg subcutaneous injection, 3 times per week Cycle Length: 12-16 weeks minimum for hair applications Break Period: 4-6 weeks between cycles Time to First Results: Subtle scalp improvements at 4-8 weeks, visible density changes at 12-16 weeks Timing considerations favor consistency above specific scheduling
Experimental studies conducted on animal models record BPC-157's effects on muscle, tendon, ligament, and gut tissue recovery
It is widely used in laboratory experiments
Vitamin D - Vitamin D deficiency is more common in people with obesity, partly because fat tissue sequesters vitamin D and reduces its bioavailability
